IDEXX Laboratories (IDXX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $1.004 billion, up 6%–6.4% year-over-year, with 7% organic growth, driven by CAG Diagnostics and Water segment gains.

• EPS was $2.44, down 9% as reported due to a $61.5–$62 million litigation expense, but comparable EPS grew 15% year-over-year.

• Record premium instrument placements and double-digit growth in recurring veterinary software and diagnostic imaging revenues supported results.

• Continued high customer retention rates (97%+), strong new business gains, and robust international performance, especially in CAG and Water.

• Net income for Q2 2024 was $203 million, down from $224 million in Q2 2023, primarily due to the litigation accrual.

Financial highlights

• Q2 organic revenue growth: 7% (CAG Diagnostics recurring: 7%, Water: 10%, LPD: 3%).

• Gross profit margin was 61.7%, up 90–100 bps year-over-year; gross profit for Q2 was $619 million.

• Operating margin for Q2 was 26.3% (down 510 bps reported due to litigation, up 110 bps comparable).

• Free cash flow for Q2 was $215 million; six months: $383 million; net income to free cash flow conversion at 99% trailing 12 months.

• Cash and cash equivalents at June 30, 2024, were $401.6 million, with working capital of $411.9 million.

Outlook and guidance

• 2024 organic revenue growth guidance updated to 6.2%–7.8% (midpoint ~7%), with full-year reported revenue guidance: $3.885B–$3.945B.

• Full-year EPS guidance: $10.31–$10.59, down $0.56 at midpoint due to litigation accrual.

• Reported operating margin outlook: 28.7%–29.0%, including a 160 bps reduction from litigation accrual.

• Q3 organic revenue growth expected at 6.5%–8.5%, with reported operating margins of 29.5%–30.0%.

• Net interest expense for 2024 projected at ~$20 million; capital expenditures at ~$180 million.